Medication info

Metformin Citrate 50/500 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
Company packaging unit
Approval status
Approval withdrawn

MFDS item code 201506301 · Approved 2015.09.01

This product's status changed to Approval withdrawn on 2023.07.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The starting dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the starting dose of metformin should take the patient's blood glucose level and current dose into account. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching to this drug in patients previously treated with other oral glucose-lowering drugs. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Blood sugar regulation disorders in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to assist in blood sugar control for patients with type 2 diabetes. It is especially beneficial for those who have not previously experienced diabetes medication treatment and find it difficult to control blood sugar with monotherapy. Additionally, it is used when metformin or sitagliptin monotherapy is insufficiently effective, or as an alternative to combination therapy with both drugs. This medication is also used to enhance treatment efficacy when blood sugar control is difficult despite the use of metformin in combination with sulfonylureas, thiazolidinediones, or insulin. It is an important therapeutic agent used in various cases to improve blood sugar control.

Dosage and Administration

Adult dosage

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The starting dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the starting dose of metformin should take the patient's blood glucose level and current dose into account. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching to this drug in patients previously treated with other oral glucose-lowering drugs. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication is used for the treatment of diabetes and helps in controlling blood sugar. During treatment, serious allergic reactions may occur. If symptoms such as skin rash or difficulty breathing occur, it is essential to stop taking the medication immediately and consult a doctor. There is a risk of acute pancreatitis, an inflammation of the pancreas, so if symptoms such as abdominal pain, vomiting, or nausea occur, visit a hospital immediately. Patients with impaired kidney function, severe infections, or dehydration should not take this medication. It is also contraindicated in patients with severe heart diseases such as severe heart failure or acute myocardial infarction, as well as in pregnant or breastfeeding women. Care is required when there are irregular meals, vigorous exercise, or concomitant use with other medications, as side effects such as hypoglycemia or lactic acidosis may occur. This medication may cause side effects such as gastrointestinal disturbances, headaches, upper respiratory infections, and hypoglycemic symptoms may also be observed. When taken with other hypoglycemic agents, the risk of hypoglycemia may increase, so blood sugar levels should be monitored closely. Since this medication is excreted by the kidneys, regular kidney function tests must be performed, and dosage adjustment or discontinuation may be necessary in cases of decreased kidney function. Moreover, it may lower vitamin B12 levels, so it is advisable to check this through regular blood tests. Excessive alcohol consumption can increase the risk of side effects associated with this medication, so it is better to avoid drinking alcohol. Patients scheduled for surgery should stop taking this medication 48 hours prior to the surgery and can resume after surgery when kidney function has been confirmed to be normal. Elderly patients are at increased risk of decreased kidney function, so they should be especially cautious in their use and undergo regular kidney function tests. In case of overdose, seek immediate medical attention, as this medication can be partially removed through hemodialysis. During the use of this medication, regular checks for blood sugar, kidney function, and blood tests should be done, and if abnormal symptoms appear, consult a doctor immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • loss of appetite
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air from entering and should be kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

Company packaging unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.